{"title":"Vaccines in Non-Small Cell Lung Cancer","authors":"L. Corrales-Rodríguez, N. Blais, D. Soulières","doi":"10.4236/WJV.2013.31004","DOIUrl":null,"url":null,"abstract":"Immunotherapy as an option \nof treatment in cancer has experienced an important development with the \ninclusion of vaccines. In lung cancer this type of treatment has emerged and \nvaccines can be classified in three groups: antigen-specific vaccines, tumor cell vaccines, \nand dendritic cell vaccines. Emepepimut (L-BLP25) and MAGE-A3 have been the \nvaccines most widely studied. Their promising results with benefit in survival \nand limited toxicity in preclinical and clinical trials have led to phase III trials with results eagerly \nawaited. Other vaccines have been investigated, but results were not favorable \nor are still pending. Hopefully, vaccines could be an additional instrument for \nthe treatment of lung cancer in the adjuvant or metastatic setting as time will \nunveil the results of current and future trials.","PeriodicalId":57190,"journal":{"name":"疫苗(英文)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"疫苗(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4236/WJV.2013.31004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Immunotherapy as an option
of treatment in cancer has experienced an important development with the
inclusion of vaccines. In lung cancer this type of treatment has emerged and
vaccines can be classified in three groups: antigen-specific vaccines, tumor cell vaccines,
and dendritic cell vaccines. Emepepimut (L-BLP25) and MAGE-A3 have been the
vaccines most widely studied. Their promising results with benefit in survival
and limited toxicity in preclinical and clinical trials have led to phase III trials with results eagerly
awaited. Other vaccines have been investigated, but results were not favorable
or are still pending. Hopefully, vaccines could be an additional instrument for
the treatment of lung cancer in the adjuvant or metastatic setting as time will
unveil the results of current and future trials.